RPID Stock Price, Rapid Micro Biosystems, . Quote, Chart

Market Summary

USD0.90-0.09

Market Closed

-9.09%

RPID Stock Price

View Fullscreen

RPID RSI Chart

RPID Valuation

Market Cap

38.9M

Price/Earnings (Trailing)

-0.75

Price/Sales (Trailing)

1.69

EV/EBITDA

-0.27

Price/Free Cashflow

-0.85

RPID Price/Sales (Trailing)

RPID Profitability

EBT Margin

-295.08%

Return on Equity

-48.99%

Return on Assets

-40.63%

Free Cashflow Yield

-117.14%

RPID Fundamentals

RPID Revenue

Revenue (TTM)

23.1M

Rev. Growth (Yr)

11.44%

Rev. Growth (Qtr)

-11.46%

RPID Earnings

Earnings (TTM)

-51.9M

Earnings Growth (Yr)

4.07%

Earnings Growth (Qtr)

-19.24%

Breaking Down RPID Revenue

Last 7 days

-5.3%

Last 30 days

-6.2%

Last 90 days

-7.2%

Trailing 12 Months

3.4%

How does RPID drawdown profile look like?

RPID Financial Health

Current Ratio

6.93

RPID Investor Care

Shares Dilution (1Y)

1.01%

Diluted EPS (TTM)

-1.21

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	23.1M	0	0	0
2023	18.0M	19.1M	20.6M	22.5M
2022	22.4M	20.1M	18.0M	17.1M
2021	17.9M	19.7M	21.4M	23.2M
2020	0	0	0	16.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Rapid Micro Biosystems, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 11, 2024	spignesi robert g. jr.	sold (taxes)	-10,126	0.981	-10,323	president and ceo
Mar 11, 2024	vezina victoria	sold (taxes)	-5,331	0.981	-5,435	chief human resources officer
Mar 11, 2024	wirtjes sean m	sold (taxes)	-7,312	0.981	-7,454	chief financial officer
Mar 11, 2024	wilson john j. addington	sold (taxes)	-9,387	0.981	-9,569	chief operating officer
Feb 12, 2024	wilson john j. addington	sold (taxes)	-5,576	0.96	-5,809	chief operating officer
Feb 12, 2024	spignesi robert g. jr.	sold (taxes)	-8,990	0.96	-9,365	president and ceo
Feb 12, 2024	vezina victoria	sold (taxes)	-2,617	0.96	-2,727	chief human resources officer
Feb 12, 2024	wirtjes sean m	sold (taxes)	-3,642	0.96	-3,794	chief financial officer
Feb 06, 2024	wilson john j. addington	acquired	-	-	39,000	chief operating officer
Feb 06, 2024	wirtjes sean m	acquired	-	-	51,000	chief financial officer

Which funds bought or sold RPID recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	KENNEDY LEWIS MANAGEMENT LP	unchanged	-	1,136,180	4,791,730	20.73%
Mar 11, 2024	VANGUARD GROUP INC	added	0.32	-245,109	538,997	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	reduced	-53.94	-700,539	323,064	-%
Feb 26, 2024	Virtu Financial LLC	new	-	12,000	12,000	-%
Feb 14, 2024	Advent International, L.P.	unchanged	-	-196,444	427,555	0.01%
Feb 14, 2024	Royal Bank of Canada	new	-	-	-	-%
Feb 14, 2024	GLENVIEW CAPITAL MANAGEMENT, LLC	unchanged	-	-448,218	975,533	0.02%
Feb 14, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	unchanged	-	-238,000	518,000	-%

Are Funds Buying or Selling RPID?

Are funds buying RPID calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RPID

No. of Funds

Unveiling Rapid Micro Biosystems, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	t. rowe price investment management, inc.	0.0%	0	SC 13G/A
Jan 22, 2024	endeavour medtech growth ii lp	6.0%	2,257,099	SC 13G/A
Feb 14, 2023	t. rowe price investment management, inc.	6.0%	2,194,185	SC 13G
Feb 14, 2023	longitude capital partners ii, llc	10.9%	4,039,845	SC 13G/A
Feb 14, 2023	d1 capital partners l.p.	0%	0	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	2.2%	800,504	SC 13G/A
Feb 08, 2023	colony harvest ltd	4.5%	1,622,260	SC 13G/A
Nov 07, 2022	jpmorgan chase & co	3.8%	1,403,862	SC 13G/A
Aug 29, 2022	kennedy lewis management lp	14.1%	5,179,061	SC 13D/A
Jun 30, 2022	kennedy lewis management lp	14.1%	5,179,061	SC 13D

Recent SEC filings of Rapid Micro Biosystems, Inc.

View All Filings

Date Filed	Form Type	Document
May 03, 2024	10-Q	Quarterly Report
May 03, 2024	8-K	Current Report
Apr 09, 2024	ARS	ARS
Apr 09, 2024	DEF 14A	DEF 14A
Apr 09, 2024	DEFA14A	DEFA14A
Mar 27, 2024	PRE 14A	PRE 14A
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading

Peers (Alternatives to Rapid Micro Biosystems, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	184.2B	40.3B	-4.83%	-4.47%	32.75	4.57	-2.84%	-3.08%
BDX	67.8B	19.7B	-3.67%	-7.05%	50.87	3.44	4.82%	-17.56%
ALGN	21.7B	3.9B	-7.16%	-5.33%	46.88	5.53	5.72%	46.72%
BAX	18.8B	14.9B	-14.74%	-18.53%	7.1	1.26	2.98%	207.68%
MID-CAP
ATR	9.7B	3.5B	4.25%	23.63%	31.11	2.75	6.16%	35.06%
HSIC	8.7B	12.3B	-7.72%	-14.36%	20.93	0.71	-2.44%	-22.68%
BIO	8.2B	2.7B	-14.65%	-39.45%	-12.84	3.06	-4.68%	82.43%
XRAY	5.9B	3.9B	-11.18%	-30.75%	-62.82	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	-3.46%	33.44%	-215.47	8.86	30.82%	65.60%
PDCO	2.3B	6.6B	-3.32%	-1.38%	11.88	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.4B	3.2B	-5.95%	-6.55%	-2.02	0.43	7.73%	-1066.14%
ANIK	408.8M	166.7M	4.91%	6.74%	-4.95	2.45	6.67%	-456.34%
ANGO	250.7M	324.0M	2.96%	-26.18%	-1.3	0.77	-3.19%	-337.41%
APYX	49.5M	52.3M	-10.06%	-59.60%	-2.65	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-19.65%	334.38%	-0.3	0.97	5.77%	8.23%

Rapid Micro Biosystems, Inc. News

Latest updates

Rapid Micro Biosystems, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	-11.5%	5,611,000	6,337,000	6,145,000	5,002,000	5,035,000	4,374,000	4,739,000	3,860,000	4,160,000	5,208,000	6,899,000	6,130,000	4,995,000	5,121,000	5,247,000	2,593,000
Costs and Expenses	7.3%	19,884,000	18,525,000	20,594,000	20,056,000	19,907,000	21,634,000	21,625,000	17,934,000	19,159,000	19,764,000	19,022,000	16,992,000	14,686,000	-	12,824,000	8,605,000
S&GA Expenses	3.8%	3,281,000	3,161,000	3,498,000	3,201,000	3,462,000	4,124,000	3,930,000	3,484,000	3,456,000	3,355,000	3,063,000	3,122,000	2,275,000	-	1,447,000	1,236,000
R&D Expenses	15.8%	3,842,000	3,318,000	3,116,000	3,233,000	3,153,000	3,403,000	2,973,000	2,965,000	3,525,000	2,855,500	2,441,000	2,337,000	2,147,000	-	2,224,000	1,244,000
EBITDA Margin	2.5%	-2.63	-2.70	-2.97	-3.21	-3.47	-3.71	-3.71	-3.39	-2.95	-3.13	-1.49	-1.63	-1.79	-1.99	-	-
Interest Expenses	-5.6%	983,000	1,041,000	1,093,000	1,073,000	1,003,000	831,000	575,000	264,000	108,000	-1,854,000	-761,000	924,000	932,000	-	886,000	814,000
Income Taxes	-62.5%	3,000	8,000	10,000	6,000	7,000	9,000	7,000	-600,000	23,000	34,000	20,000	18,000	19,000	-	20,000	74,000
Earnings Before Taxes	-	-	-	-	-	-	-	-	-13,703,000	-14,907,000	-14,571,000	-24,967,000	-11,813,000	-22,082,000	-	-8,445,000	-9,193,000
EBT Margin	2.5%	-2.95	-3.03	-3.32	-3.56	-3.78	-3.98	-3.79	-3.39	-2.96	-3.16	-1.72	-1.88	-2.07	-2.30	-	-
Net Income	-19.2%	-13,322,000	-11,172,000	-13,392,000	-14,016,000	-13,887,000	-16,447,000	-16,339,000	-13,090,000	-14,930,000	-14,605,000	-24,987,000	-11,831,000	-22,101,000	-11,339,000	-8,465,000	-9,267,000
Net Income Margin	3.5%	-2.25	-2.33	-2.81	-3.17	-3.32	-3.55	-3.28	-3.36	-2.96	-3.16	-3.28	-2.73	-2.86	-2.31	-	-
Free Cashflow	-62.5%	-16,110,000	-9,915,000	-10,161,000	-9,405,000	-17,445,000	-12,466,000	-16,692,000	-16,975,000	-19,154,000	-14,853,000	-19,768,000	-12,047,000	-11,513,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-11.0%	128	143	150	161	173	191	202	216	230	241	254	129	70.00
Current Assets	-10.2%	108	120	115	133	129	139	145	171	187	218	244	118	62.00
Cash Equivalents	-6.5%	23.00	24.00	24.00	29.00	24.00	27.00	26.00	50.00	63.00	179	220	100	30.00
Inventory	2.3%	20.00	20.00	20.00	21.00	21.00	21.00	21.00	21.00	18.00	16.00	14.00	12.00	9.00
Net PPE	-1.7%	13.00	13.00	13.00	13.00	14.00	14.00	13.00	13.00	12.00	11.00	9.00	7.00	7.00
Liabilities	-14.4%	22.00	25.00	22.00	21.00	21.00	26.00	23.00	21.00	23.00	20.00	20.00	58.00	45.00
Current Liabilities	-17.8%	16.00	19.00	16.00	14.00	14.00	19.00	15.00	13.00	15.00	18.00	18.00	16.00	16.00
Shareholder's Equity	-10.2%	106	118	128	140	152	164	179	195	207	221	235	-	-
Retained Earnings	-3.1%	-441	-428	-417	-403	-389	-375	-359	-343	-330	-315	-300	-275	-241
Additional Paid-In Capital	0.2%	547	546	545	544	542	541	539	539	537	536	535	111	115
Shares Outstanding	0.5%	43.00	43.00	43.00	43.00	43.00	42.00	42.00	42.00	42.00	20.00	12.00	156	-
Float	-	-	-	-	28.00	-	-	-	24.00	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-63.5%	-15,525	-9,497	-9,708	-9,190	-16,686	-11,655	-15,105	-14,986	-16,801	-12,887	-19,309	-11,506	-11,262	-	-	-
Share Based Compensation	6.2%	1,085	1,022	1,251	1,234	1,243	1,105	673	1,258	983	678	584	390	191	-	-	-
Cashflow From Investing	35.0%	13,515	10,008	4,766	13,469	13,910	12,800	-8,934	2,213	-99,548	-27,058	-459	4,479	9,749	-	-	-
Cashflow From Financing	1416.7%	158	-12.00	48.00	-9.00	122	87.00	151	-8.00	463	-1,256	139,309	-1,377	80,069	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RPID Income Statement

2023-12-31

Consolidated statements of operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenue:
Total revenue	$ 22,519	$ 17,133
Costs and operating expenses:
Research and development	12,820	12,866
Sales and marketing	13,322	14,994
General and administrative	24,936	26,819
Total costs and operating expenses	79,082	80,352
Loss from operations	(56,563)	(63,219)
Other income (expense):
Interest income, net	4,210	1,778
Other (expense) income, net	(83)	59
Total other income, net	4,127	1,837
Loss before income taxes	(52,436)	(61,382)
Income tax expense (benefit)	31	(576)
Net loss	$ (52,467)	$ (60,806)
Net loss per share — basic (in dollars per share)	$ (1.22)	$ (1.43)
Net loss per share — diluted (in dollars per share)	$ (1.22)	$ (1.43)
Weighted average common shares outstanding - basic (in shares)	43,024,039	42,454,403
Weighted average common shares outstanding - diluted (in shares)	43,024,039	42,454,403
Product
Revenue:
Total revenue	$ 14,805	$ 11,056
Costs and operating expenses:
Cost of revenue	20,060	18,477
Service
Revenue:
Total revenue	7,714	6,077
Costs and operating expenses:
Cost of revenue	$ 7,944	$ 7,196

RPID Balance Sheet

2023-12-31

Consolidated balance sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 24,285	$ 27,064
Short-term investments	67,768	81,584
Accounts receivable	5,532	5,369
Inventory	19,961	21,187
Prepaid expenses and other current assets	2,869	3,372
Total current assets	120,415	138,576
Property and equipment, net	12,832	13,818
Right-of-use assets	6,240	7,063
Long-term investments	2,911	29,790
Other long-term assets	770	1,119
Restricted cash	284	284
Total assets	143,452	190,650
Current liabilities:
Accounts payable	1,973	5,428
Accrued expenses and other current liabilities	9,907	8,150
Deferred revenue	5,974	4,706
Lease liabilities, short-term	1,132	766
Total current liabilities	18,986	19,050
Lease liabilities, long-term	6,214	7,202
Other long-term liabilities	263	229
Total liabilities	25,463	26,481
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred stock	0	0
Additional paid-in capital	546,051	540,775
Accumulated deficit	(428,385)	(375,918)
Accumulated other comprehensive loss	(101)	(1,109)
Total stockholders’ equity	117,989	164,169
Total liabilities and stockholders’ equity	143,452	190,650
Class A Common stock
Stockholders’ equity:
Common stock	371	366
Class B Common stock
Stockholders’ equity:
Common stock	$ 53	$ 55

About Rapid Micro Biosystems, Inc.

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, onsite technical training, and customer support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. In addition, it offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; and RMBNucleus Central Manager portal streamlines monitoring and reporting. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

CEO	Mr. Robert G. Spignesi Jr.
WEBSITE	rapidmicrobio.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	177

Rapid Micro Biosystems, Inc. Frequently Asked Questions

What is the ticker symbol for Rapid Micro Biosystems, Inc.? What does RPID stand for in stocks?

RPID is the stock ticker symbol of Rapid Micro Biosystems, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Rapid Micro Biosystems, Inc. (RPID)?

As of Fri May 03 2024, market cap of Rapid Micro Biosystems, Inc. is 38.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RPID stock?

You can check RPID's fair value in chart for subscribers.

What is the fair value of RPID stock?

You can check RPID's fair value in chart for subscribers. The fair value of Rapid Micro Biosystems, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Rapid Micro Biosystems, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RPID so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Rapid Micro Biosystems, Inc. a good stock to buy?

The fair value guage provides a quick view whether RPID is over valued or under valued. Whether Rapid Micro Biosystems, Inc. is cheap or expensive depends on the assumptions which impact Rapid Micro Biosystems, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RPID.

What is Rapid Micro Biosystems, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 03 2024, RPID's PE ratio (Price to Earnings) is -0.74 and Price to Sales (PS) ratio is 1.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RPID PE ratio will change depending on the future growth rate expectations of investors.